Avinza Elan.

Author(s): Semenchuk MR

Affiliation(s): Marilyn.R.Semenchuk@gsk.com

Publication date & source: 2002-09, Curr Opin Investig Drugs., 3(9):1369-72.

Publication type: Review

Avinza is a once-daily morphine sulfate controlled-release formulation utilizing SODAS (Spheroidal Oral Drug Absorption System) technology developed by Elan and Ligand for the potential treatment of pain [220806], [223862]. This multiparticulate product is designed to provide a rapid onset of action together with a sustained therapeutic effect over 24 h. It is thought that once-daily administration should improve compliance and help eliminate breakthrough pain which is a feature of many twice-daily products, thereby providing better pain management [220806].